ArticleNeuro-oncology2014
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
David E Piccioni et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this paperpooled ittrialcites it